Laboratory Medicine ›› 2019, Vol. 34 ›› Issue (2): 116-121.DOI: 10.3969/j.issn.1673-8640.2019.02.005
Previous Articles Next Articles
ZHANG Boke1, HUANG Yi2, LIU Yiwen1, HE Yiqing1, YANG Cuixia1, DU Yan1, ZHANG Guoliang1, GAO Feng2()
Received:
2018-08-31
Online:
2019-02-28
Published:
2019-02-28
CLC Number:
ZHANG Boke, HUANG Yi, LIU Yiwen, HE Yiqing, YANG Cuixia, DU Yan, ZHANG Guoliang, GAO Feng. Combined determination of plasma hyaluronan and the ratio of M2 monocyte/M1 monocyte ratio in breast cancer[J]. Laboratory Medicine, 2019, 34(2): 116-121.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2019.02.005
组别 | 例数 | 年龄(岁) | 白细胞(×109/L) | 单核细胞(×109/L) | HA(ng/mL) |
---|---|---|---|---|---|
乳腺癌组 | 98 | 50.50±10.19 | 5.79±1.65 | 0.35±0.10 | 71.25(55.79~96.08) |
乳腺良性疾病组 | 37 | 49.35±8.26 | 5.86±1.18 | 0.36±0.13 | 49.36(43.83~56.13)* |
正常对照组 | 41 | 49.52±9.78 | 5.28±1.22 | 0.32±0.11 | 48.70(45.82~54.64)* |
组别 | CA15-3(U/mL) | M1型单核细胞比例(%) | M2型单核细胞比例(%) | M2/M1比值 | |
乳腺癌组 | 11.06(7.82~16.30) | 30.85±5.52# | 5.71±1.52 | 0.193±0.070 | |
乳腺良性疾病组 | 8.15(6.64~11.82)* | 39.11±4.97 | 3.90±0.98* | 0.087±0.028* | |
正常对照组 | 9.82(6.75~12.09)* | 32.58±5.31# | 3.76±1.22* | 0.103±0.035* |
组别 | 例数 | 年龄(岁) | 白细胞(×109/L) | 单核细胞(×109/L) | HA(ng/mL) |
---|---|---|---|---|---|
乳腺癌组 | 98 | 50.50±10.19 | 5.79±1.65 | 0.35±0.10 | 71.25(55.79~96.08) |
乳腺良性疾病组 | 37 | 49.35±8.26 | 5.86±1.18 | 0.36±0.13 | 49.36(43.83~56.13)* |
正常对照组 | 41 | 49.52±9.78 | 5.28±1.22 | 0.32±0.11 | 48.70(45.82~54.64)* |
组别 | CA15-3(U/mL) | M1型单核细胞比例(%) | M2型单核细胞比例(%) | M2/M1比值 | |
乳腺癌组 | 11.06(7.82~16.30) | 30.85±5.52# | 5.71±1.52 | 0.193±0.070 | |
乳腺良性疾病组 | 8.15(6.64~11.82)* | 39.11±4.97 | 3.90±0.98* | 0.087±0.028* | |
正常对照组 | 9.82(6.75~12.09)* | 32.58±5.31# | 3.76±1.22* | 0.103±0.035* |
项目 | AUC(95%可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HA | 0.849(0.787~0.911) | 61.15 ng/mL | 61.22 | 95.12 |
CA15-3 | 0.638(0.544~0.732) | 13.67 U/mL | 35.71 | 92.68 |
M1型单核细胞比例 | 0.599(0.495~0.703) | 35.35% | 82.65 | 41.46 |
M2型单核细胞比例 | 0.852(0.779~0.923) | 4.99% | 71.43 | 87.80 |
M2/M1比值 | 0.909(0.860~0.957) | 0.138 | 80.60 | 85.37 |
HA+ M2/M1比值联合检测 | 0.952(0.918~0.987) | 90.82 | 92.68 |
项目 | AUC(95%可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HA | 0.849(0.787~0.911) | 61.15 ng/mL | 61.22 | 95.12 |
CA15-3 | 0.638(0.544~0.732) | 13.67 U/mL | 35.71 | 92.68 |
M1型单核细胞比例 | 0.599(0.495~0.703) | 35.35% | 82.65 | 41.46 |
M2型单核细胞比例 | 0.852(0.779~0.923) | 4.99% | 71.43 | 87.80 |
M2/M1比值 | 0.909(0.860~0.957) | 0.138 | 80.60 | 85.37 |
HA+ M2/M1比值联合检测 | 0.952(0.918~0.987) | 90.82 | 92.68 |
项目 | AUC(95%可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HA | 0.839(0.772~0.905) | 61.17 ng/mL | 60.20 | 89.19 |
CA15-3 | 0.631(0.529~0.733) | 13.70 U/mL | 34.68 | 83.78 |
M1型单核细胞比例 | 0.870(0.808~0.931) | 35.69% | 85.71 | 75.68 |
M2型单核细胞比例 | 0.851(0.785~0.918) | 5.00% | 69.39 | 86.49 |
M2/M1比值 | 0.960(0.911~0.984) | 0.127 | 89.80 | 91.89 |
HA+ M2/M1比值联合检测 | 0.973(0.949~0.997) | 91.84 | 97.30 |
项目 | AUC(95%可信区间) | 最佳临界值 | 敏感性(%) | 特异性(%) |
---|---|---|---|---|
HA | 0.839(0.772~0.905) | 61.17 ng/mL | 60.20 | 89.19 |
CA15-3 | 0.631(0.529~0.733) | 13.70 U/mL | 34.68 | 83.78 |
M1型单核细胞比例 | 0.870(0.808~0.931) | 35.69% | 85.71 | 75.68 |
M2型单核细胞比例 | 0.851(0.785~0.918) | 5.00% | 69.39 | 86.49 |
M2/M1比值 | 0.960(0.911~0.984) | 0.127 | 89.80 | 91.89 |
HA+ M2/M1比值联合检测 | 0.973(0.949~0.997) | 91.84 | 97.30 |
临床病理特征 | 例数 | CA15-3(U/mL) | M2/M1比值 | HA(ng/mL) |
---|---|---|---|---|
年龄(岁) | ||||
≤50 | 46 | 11.25 (8.21~15.62) | 0.186±0.060 | 65.32 (62.15~89.57) |
>50 | 52 | 10.92 (8.18~15.72) | 0.198±0.070 | 77.15 (68.56~96.28) |
P值 | 0.822 | 0.368 | 0.176 | |
肿瘤大小(cm) | ||||
≤2.0 | 39 | 10.58 (7.78~15.75) | 0.183±0.080 | 75.13 (63.52~90.36) |
>2.0 | 59 | 11.16 (8.26~16.39) | 0.199±0.060 | 81.56 (60.75~91.39) |
P值 | 0.119 | 0.261 | 0.611 | |
TNM分期 | ||||
0~Ⅰ期 | 32 | 10.53(7.27~12.59) | 0.139±0.050 | 67.98(63.51~82.65) |
Ⅱ期 | 50 | 12.22(8.39~18.35) | 0.195±0.070 | 72.55(61.37~95.33) |
Ⅲ~Ⅳ期 | 16 | 12.53(7.63~18.86) | 0.296±0.060 | 80.07(61.21~138.9) |
P值 | 0.075 | 0.000 | 0.553 | |
临床病理特征 | 例数 | CA15-3(U/mL) | M2/M1比值 | HA(ng/mL) |
组织学类型 | ||||
浸润性导管癌 | 73 | 11.35 (8.21~17.39) | 0.195±0.080 | 71.66 (63.25~90.36) |
其他 | 25 | 10.56 (8.52~15.06) | 0.188±0.070 | 74.19 (60.59~102.93) |
P值 | 0.229 | 0.698 | 0.522 | |
组织学分化 | ||||
中~高分化 | 36 | 11.16 (8.30~16.66) | 0.151±0.050 | 66.43 (60.75~85.71) |
低分化 | 62 | 10.25 (8.10~15.23) | 0.218±0.060 | 82.89 (66.12~112.8) |
P值 | 0.513 | 0.000 | 0.005 | |
淋巴结转移 | ||||
N0 | 45 | 10.76 (8.15~14.85) | 0.149±0.050 | 71.33 (63.25~89.27) |
N1~3 | 53 | 12.25 (8.33~17.20) | 0.230±0.070 | 73.36 (61.27~97.29) |
P值 | 0.208 | 0.000 | 0.611 | |
ER | ||||
阳性 | 68 | 11.17 (8.56~16.07) | 0.165±0.050 | 68.38 (62.15~85.27) |
阴性 | 30 | 10.56 (7.88~15.59) | 0.256±0.070 | 81.18 (61.21~119.9) |
P值 | 0.561 | 0.000 | 0.191 | |
PR | ||||
阳性 | 61 | 10.58 (8.63~15.17) | 0.188±0.070 | 71.32 (61.35~87.59) |
阴性 | 37 | 12.15 (7.90~18.19) | 0.201±0.060 | 75.73 (62.28~105.37) |
P值 | 0.198 | 0.350 | 0.501 | |
HER-2 | ||||
阳性 | 21 | 11.15 (7.12~18.16) | 0.211±0.070 | 65.28 (60.72~85.93) |
阴性 | 77 | 10.88 (8.18~15.04) | 0.188±0.060 | 75.08 (63.55~96.17) |
P值 | 0.794 | 0.137 | 0.102 |
临床病理特征 | 例数 | CA15-3(U/mL) | M2/M1比值 | HA(ng/mL) |
---|---|---|---|---|
年龄(岁) | ||||
≤50 | 46 | 11.25 (8.21~15.62) | 0.186±0.060 | 65.32 (62.15~89.57) |
>50 | 52 | 10.92 (8.18~15.72) | 0.198±0.070 | 77.15 (68.56~96.28) |
P值 | 0.822 | 0.368 | 0.176 | |
肿瘤大小(cm) | ||||
≤2.0 | 39 | 10.58 (7.78~15.75) | 0.183±0.080 | 75.13 (63.52~90.36) |
>2.0 | 59 | 11.16 (8.26~16.39) | 0.199±0.060 | 81.56 (60.75~91.39) |
P值 | 0.119 | 0.261 | 0.611 | |
TNM分期 | ||||
0~Ⅰ期 | 32 | 10.53(7.27~12.59) | 0.139±0.050 | 67.98(63.51~82.65) |
Ⅱ期 | 50 | 12.22(8.39~18.35) | 0.195±0.070 | 72.55(61.37~95.33) |
Ⅲ~Ⅳ期 | 16 | 12.53(7.63~18.86) | 0.296±0.060 | 80.07(61.21~138.9) |
P值 | 0.075 | 0.000 | 0.553 | |
临床病理特征 | 例数 | CA15-3(U/mL) | M2/M1比值 | HA(ng/mL) |
组织学类型 | ||||
浸润性导管癌 | 73 | 11.35 (8.21~17.39) | 0.195±0.080 | 71.66 (63.25~90.36) |
其他 | 25 | 10.56 (8.52~15.06) | 0.188±0.070 | 74.19 (60.59~102.93) |
P值 | 0.229 | 0.698 | 0.522 | |
组织学分化 | ||||
中~高分化 | 36 | 11.16 (8.30~16.66) | 0.151±0.050 | 66.43 (60.75~85.71) |
低分化 | 62 | 10.25 (8.10~15.23) | 0.218±0.060 | 82.89 (66.12~112.8) |
P值 | 0.513 | 0.000 | 0.005 | |
淋巴结转移 | ||||
N0 | 45 | 10.76 (8.15~14.85) | 0.149±0.050 | 71.33 (63.25~89.27) |
N1~3 | 53 | 12.25 (8.33~17.20) | 0.230±0.070 | 73.36 (61.27~97.29) |
P值 | 0.208 | 0.000 | 0.611 | |
ER | ||||
阳性 | 68 | 11.17 (8.56~16.07) | 0.165±0.050 | 68.38 (62.15~85.27) |
阴性 | 30 | 10.56 (7.88~15.59) | 0.256±0.070 | 81.18 (61.21~119.9) |
P值 | 0.561 | 0.000 | 0.191 | |
PR | ||||
阳性 | 61 | 10.58 (8.63~15.17) | 0.188±0.070 | 71.32 (61.35~87.59) |
阴性 | 37 | 12.15 (7.90~18.19) | 0.201±0.060 | 75.73 (62.28~105.37) |
P值 | 0.198 | 0.350 | 0.501 | |
HER-2 | ||||
阳性 | 21 | 11.15 (7.12~18.16) | 0.211±0.070 | 65.28 (60.72~85.93) |
阴性 | 77 | 10.88 (8.18~15.04) | 0.188±0.060 | 75.08 (63.55~96.17) |
P值 | 0.794 | 0.137 | 0.102 |
[1] | DUFFY M J,EVOY D,MCDERMOTT E W.CA 15-3:uses and limitation as a biomarker for breast cancer[J]. Clin Chim Acta,2010,411(23-24):1869-1874. |
[2] | SOUSA S,BRION R,LINTUNEN M,et al.Human breast cancer cells educate macrophages toward the M2 activation status[J]. Breast Cancer Res,2015,17:101. |
[3] | ROUSSOS E T,BALSAMO M,ALFORD S K,et al.Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer[J]. J Cell Sci,2011,124(Pt 13):2120-2131. |
[4] | ADAMS D L,MARTIN S S,ALPAUGH R K,et al.Circulating giant macrophages as a potential biomarker of solid tumors[J]. Proc Natl Acad Sci U S A,2014,111(9):3514-3519. |
[5] | SICA A,SCHIOPPA T,MANTOVANI A,et al.Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression:potential targets of anti-cancer therapy[J]. Eur J Cancer,2006,42(6):717-727. |
[6] | ZHANG B,CAO M,HE Y,et al.Increased circulating M2-like monocytes in patients with breast cancer[J]. Tumour Biol,2017,39(6):1010428317711571. |
[7] | WU M,CAO M,HE Y,et al.A novel role of low molecular weight hyaluronan in breast cancer metastasis[J]. FASEB J,2015,29(4):1290-1298. |
[8] | TIAINEN S,TUMELIUS R,RILLA K,et al.High numbers of macrophages,especially M2-like(CD163-positive),correlate with hyaluronan accumulation and poor outcome in breast cancer[J]. Histopathology,2015,66(6):873-883. |
[9] | MANTOVANI A,SOZZANI S,LOCATI M,et al.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes[J]. Trends Immunol,2002,23(11):549-555. |
[10] | MAEDA R,ISHII G,NERI S,et al.Circulating CD14+CD204+ cells predict postoperative recurrence in non-small-cell lung cancer patients[J]. J Thorac Oncol,2014,9(2):179-188. |
[11] | LI C,LUO X,LIN Y,et al.A higher frequency of CD14+ CD169+ monocytes/macrophages in patients with colorectal cancer[J]. PLoS One,2015,10(10):e0141817. |
[12] | OSTUNI R,KRATOCHVILL F,MURRAY P J,et al.Macrophages and cancer:from mechanisms to therapeutic implications[J]. Trends Immunol,2015,36(4):229-239. |
[13] | CLAWSON G A,MATTERS G L,XIN P,et al.Macrophage-tumor cell fusions from peripheral blood of melanoma patients[J]. PLoS One,2015,10(8):e0134320. |
[14] | KUANG D M,WU Y,CHEN N,et al.Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes[J]. Blood,2007,110(2):587-595. |
[1] | WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817. |
[2] | CHEN Chen, DUAN Qi, LU Jiatuan, ZHAI Xiaojian, WANG Zheng, ZHANG Hao, GUO Man. Expressions of ASH2L and HOXA2 in triple-negative breast cancer patients and their relationship with lymph node metastasis [J]. Laboratory Medicine, 2023, 38(6): 574-578. |
[3] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Changes of serum HAS2 and CD44 levels in breast cancer patients and their clinical significance [J]. Laboratory Medicine, 2023, 38(5): 424-429. |
[4] | ZHANG Guoliang, LIU Yiwen, HE Yiqing, XU Jing, YANG Cuixia, GAO Feng, LIU Hua. Roles of serum HYAL1 and HA in the auxiliary diagnosis and therapeutic monitoring of colorectal cancer [J]. Laboratory Medicine, 2023, 38(4): 313-319. |
[5] | LIU Qinqing, XU Jing, LIU Hua, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of hyaluronan in thyroid nodule fine-needle aspiration washout fluid in differential diagnosis of papillary thyroid cancer [J]. Laboratory Medicine, 2023, 38(4): 320-324. |
[6] | LI Mu, GONG Dongliang, XU Liming, PENG Rong. Relationship of XPC rs2228000 polymorphisms and breast cancer [J]. Laboratory Medicine, 2023, 38(3): 235-239. |
[7] | LIU Chong, ZHANG Jing, LI Sheng, ZHAO Qi. Expressions and correlation of miR-335 and Fra-1 in breast cancer [J]. Laboratory Medicine, 2023, 38(2): 143-147. |
[8] | GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206,miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068. |
[9] | WANG Xiaoye, DONG Guoyou, LIU Zhiying. Relations of ZEB2 and E-Cad expressions in breast cancer tissues with prognosis [J]. Laboratory Medicine, 2022, 37(9): 815-820. |
[10] | YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517. |
[11] | YE Jingwen, SHEN Yunyue, LIU Yiwen, HE Yiqing, DU Yan, ZHANG Guoliang, GAO Feng, YANG Cuixia. Role of MAPK/ERK signaling pathway in reversing endocrine resistance of breast cancer [J]. Laboratory Medicine, 2022, 37(4): 342-348. |
[12] | ZHANG Xinyue, CHEN Liang, ZHENG Yu. Correlation between serum C peptide and insulin-like growth factor binding protein 3 and the risk of breast cancer patient death [J]. Laboratory Medicine, 2022, 37(1): 36-40. |
[13] | LIN Jiafei, CHEN Xiaosong, WU Beiying, CAI Gang, LIN Lin. 21-Gene recurrence score in mucinous breast cancer [J]. Laboratory Medicine, 2021, 36(7): 714-718. |
[14] | YUAN Muge, WU Wenjian, HU Zhaohui, CHEN Jiachang, YU Shihui, OU Xiaohua, MAO Linlin, WU Haiyan. Germline mutation detection in early-stage breast cancer by next-generation sequencing [J]. Laboratory Medicine, 2021, 36(3): 325-329. |
[15] | SHENG Yumeng, XU Jing, LIU Yiwen, HE Yiqing, LIU Hua, HUANG Yi, HU Jiajie, CUI Lian, GAO Feng, YANG Cuixia. Clinical value of combined detection of serum HA and HAS2 in diagnosis and therapeutic monitoring of bone tumors [J]. Laboratory Medicine, 2021, 36(2): 162-166. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||